|
1
|
Berruti A, Generali D, Kaufmann M, Puztai
L, Curigliano G, Aglietta M, Gianni L, Miller WR, Untch M, Sotiriou
C, et al: International expert consensus on primary systemic
therapy in the management of early breast cancer: highlights of the
Fourth Symposium on Primary Systemic Therapy in the Management of
Operable Breast Cancer; Cremona, Italy. 2010; J Natl Cancer Inst
Monogr. 2011. pp. 147–151. 2011, View Article : Google Scholar
|
|
2
|
Kaufmann M, von Minckwitz G, Mamounas EP,
Cameron D, Carey LA, Cristofanilli M, Denkert C, Eiermann W, Gnant
M, Harris JR, et al: Recommendations from an international
consensus conference on the current status and future of
neoadjuvant systemic therapy in primary breast cancer. Ann Surg
Oncol. 19:1508–1516. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Burcombe RJ, Makris A, Richman PI, Daley
FM, Noble S, Pittam M, Wright D, Allen SA, Dove J and Wilson GD:
Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to
neoadjuvant anthracycline chemotherapy for operable breast cancer.
Br J Cancer. 92:147–155. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hirata T, Shimizu C, Yonemori K, Hirakawa
A, Kouno T, Tamura K, Ando M, Katsumata N and Fujiwara Y: Change in
the hormone receptor status following administration of neoadjuvant
chemotherapy and its impact on the long-term outcome in patients
with primary breast cancer. Br J Cancer. 101:1529–1536. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jain V, Landry M and Levine EA: The
stability of estrogen and progesterone receptors in patients
receiving preoperative chemotherapy for locally advanced breast
carcinoma. Am Surg. 62:162–165. 1996.PubMed/NCBI
|
|
6
|
Tacca O, Penault-Llorca F, Abrial C,
Mouret-Reynier MA, Raoelfils I, Durando X, Achard JL, Gimbergues P,
Curé H and Chollet P: Changes in and prognostic value of hormone
receptor status in a series of operable breast cancer patients
treated with neoadjuvant chemotherapy. Oncologist. 12:636–643.
2007. View Article : Google Scholar
|
|
7
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar
|
|
8
|
Chen X, Yuan Y, Gu Z and Shen K: Accuracy
of estrogen receptor, progesterone receptor, and HER2 status
between core needle and open excision biopsy in breast cancer: a
meta-analysis. Breast Cancer Res Treat. 134:957–967. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang N, Moran MS, Huo Q, Haffty BG and
Yang Q: The hormonal receptor status in breast cancer can be
altered by neoadjuvant chemotherapy: a meta-analysis. Cancer
Invest. 29:594–598. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
van de Ven S, Smit VT, Dekker TJ, Nortier
JW and Kroep JR: Discordances in ER, PR and HER2 receptors after
neoadjuvant chemotherapy in breast cancer. Cancer Treat Rev.
37:422–430. 2011.PubMed/NCBI
|
|
11
|
Goldhirsch A, Wood WC, Coates AS, Gelber
RD, Thürlimann B and Senn HJ; Panel members. Strategies for
subtypes - dealing with the diversity of breast cancer: highlights
of the St. Gallen International Expert Consensus on the Primary
Therapy of Early Breast Cancer 2011. Ann Oncol. 22:1736–1747. 2011.
View Article : Google Scholar
|
|
12
|
Perou CM, Sørlie T, Eisen MB, van de Rijn
M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA,
et al: Molecular portraits of human breast tumours. Nature.
406:747–752. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sørlie T, Perou CM, Tibshirani R, Aas T,
Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey
SS, et al: Gene expression patterns of breast carcinomas
distinguish tumor subclasses with clinical implications. Proc Natl
Acad Sci USA. 98:10869–10874. 2001.PubMed/NCBI
|
|
14
|
Chen XS, Wu JY, Huang O, Chen CM, Wu J, Lu
JS, Shao ZM, Shen ZZ and Shen KW: Molecular subtype can predict the
response and outcome of Chinese locally advanced breast cancer
patients treated with preoperative therapy. Oncol Rep.
23:1213–1220. 2010.PubMed/NCBI
|
